AML Remote Monitoring (Acute Myeloid Leukemia) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to collect symptom and treatment experience data from patients with acute myelogenous leukemia (AML) being seen at the Duke Cancer Institute. We will add this data to a data registry and use it to identify quality improvement opportunities.
Acute Myeloid Leukemia (AML)
Who Can Participate in the Study?
Adults who:
- Are diagnosed with AML and currently receiving treatment
- Have the ability to complete online surveys using a cell phone, tablet, or computer
For more information about who can join this study, please contact the study team at sarah.lacinski@duke.edu
What is Involved?
If you choose to join this study, you will fill out a baseline survey and weekly electronic surveys for at least 12 weeks. The surveys will ask you about the symptoms you experience as you go through your AML treatments.
Study Details
